$PCRX
Pacira BioSciences, Inc. Stock $pcrx

$pcrx Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000162828016015255 Filed on May 02, 2016

Income Statement

Concept	2016 Q1	2015 Q1
Revenue	$65.47M	$58.32M
YoY Change	12.27%	59.06%
Cost Of Revenue	$20.28M	$17.58M
YoY Change	15.35%	-3.02%
Gross Profit	$45.20M	$40.74M
YoY Change	10.95%	119.78%
Gross Profit Margin	69.03%	69.85%
Selling, General & Admin	$37.96M	$31.43M
YoY Change	20.77%	39.13%
% of Gross Profit	83.98%	77.15%
Research & Development	$9.493M	$5.967M
YoY Change	59.09%	14.66%
% of Gross Profit	21.0%	14.65%
Depreciation & Amortization	$3.165M	$2.743M
YoY Change	15.38%	5.38%
% of Gross Profit	7.0%	6.73%
Operating Expenses	$67.73M	$54.98M
YoY Change	23.2%	19.72%
Operating Profit	-$2.254M	$3.341M
YoY Change	-167.46%	-136.09%
Interest Expense	$1.868M	$1.996M
YoY Change	-6.41%	-5.27%
% of Operating Profit		59.74%
Other Income/Expense, Net	-$1.568M	-$2.029M
YoY Change	-22.72%	-8.56%
Pretax Income	-$3.822M	$1.312M
YoY Change	-391.31%	-111.43%
Income Tax	$32.00K	$52.00K
% Of Pretax Income		3.96%
Net Earnings	-$3.854M	$1.260M
YoY Change	-405.87%	-110.98%
Net Earnings / Revenue	-5.89%	2.16%
Basic Earnings Per Share	-$0.10
Diluted Earnings Per Share	-$105.4K	$31.10K
COMMON SHARES
Basic Shares Outstanding	37.02M shares	36.24M shares
Diluted Shares Outstanding	37.02M shares	41.78M shares

Balance Sheet

Concept	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$150.0M	$154.9M
YoY Change	-3.16%	139.78%
Cash & Equivalents	$35.03M	$40.90M
Short-Term Investments	$115.0M	$114.0M
Other Short-Term Assets	$9.000M	$4.100M
YoY Change	119.51%	57.69%
Inventory	$63.74M	$36.26M
Prepaid Expenses
Receivables	$25.90M	$24.51M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$248.6M	$219.8M
YoY Change	13.14%	123.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$95.85M	$67.21M
YoY Change	42.62%	34.71%
Goodwill	$32.78M	$25.38M
YoY Change	29.17%	124.08%
Intangibles
YoY Change
Long-Term Investments	$13.50M	$19.90M
YoY Change	-32.16%
Other Assets	$481.0K	$2.432M
YoY Change	-80.22%	-27.47%
Total Long-Term Assets	$142.6M	$115.3M
YoY Change	23.68%	76.77%
TOTAL ASSETS
Total Short-Term Assets	$248.6M	$219.8M
Total Long-Term Assets	$142.6M	$115.3M
Total Assets	$391.2M	$335.0M
YoY Change	16.77%	104.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.48M	$5.565M
YoY Change	88.39%	113.63%
Accrued Expenses	$29.07M	$25.30M
YoY Change	14.91%	49.57%
Deferred Revenue
YoY Change
Short-Term Debt	$105.2M	$104.1M
YoY Change	1.06%	4.1%
Long-Term Debt Due		$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$146.1M	$136.5M
YoY Change	7.1%	12.23%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$11.02M	$5.404M
YoY Change	103.92%	57.32%
Total Long-Term Liabilities	$11.02M	$5.404M
YoY Change	103.92%	57.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$146.1M	$136.5M
Total Long-Term Liabilities	$11.02M	$5.404M
Total Liabilities	$165.0M	$151.0M
YoY Change	9.29%	17.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$312.1M	-$308.9M
YoY Change	1.05%	0.32%
Common Stock	$37.00K	$36.00K
YoY Change	2.78%	5.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares	0.000 shares	0.000 shares
Shareholders Equity	$226.2M	$184.0M
YoY Change
Total Liabilities & Shareholders Equity	$391.2M	$335.0M
YoY Change	16.77%	104.67%

Cashflow Statement

Concept	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$3.854M	$1.260M
YoY Change	-405.87%	-110.98%
Depreciation, Depletion And Amortization	$3.165M	$2.743M
YoY Change	15.38%	5.38%
Cash From Operating Activities	-$3.120M	-$870.0K
YoY Change	258.62%	-81.65%
INVESTING ACTIVITIES
Capital Expenditures	$7.053M	$7.874M
YoY Change	-10.43%	106.78%
Acquisitions
YoY Change
Other Investing Activities	-$14.82M	$8.070M
YoY Change	-283.64%	-37.1%
Cash From Investing Activities	-$21.88M	$200.0K
YoY Change	-11040.0%	-97.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.041M	$4.047M
YoY Change	-24.86%	106.06%
NET CHANGE
Cash From Operating Activities	-3.120M	-870.0K
Cash From Investing Activities	-21.88M	200.0K
Cash From Financing Activities	$3.041M	$4.047M
Net Change In Cash	$3.041M	$4.047M
YoY Change	-24.86%	106.06%
FREE CASH FLOW
Cash From Operating Activities	-$3.120M	-$870.0K
Capital Expenditures	$7.053M	$7.874M
Free Cash Flow	-$10.17M	-$8.744M
YoY Change	16.34%	2.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001396814
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37167255	shares
CY2016Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	Pacira Pharmaceuticals, Inc.
CY2015Q1	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	122000	USD
CY2016Q1	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	120000	USD
CY2015Q1	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	356000	USD
CY2016Q1	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	356000	USD
CY2015Q1	pcrx	Compensationexpensefromemployeestockpurchaseplan Compensationexpensefromemployeestockpurchaseplan	211000	USD
CY2016Q1	pcrx	Compensationexpensefromemployeestockpurchaseplan Compensationexpensefromemployeestockpurchaseplan	275000	USD
CY2015Q1	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	6309000	USD
CY2016Q1	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	6856000	USD
CY2015Q1	pcrx	Compensationexpensefromstockoptionsnonemployeeawards Compensationexpensefromstockoptionsnonemployeeawards	997000	USD
CY2016Q1	pcrx	Compensationexpensefromstockoptionsnonemployeeawards Compensationexpensefromstockoptionsnonemployeeawards	274000	USD
CY2012Q2	pcrx	Contingent Payment Obligation Established For Sale Of Product In Connection With Acquisition ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition	2000000	USD
CY2016Q1	pcrx	Debt Instrument Convertible Conversion Premium Shares DebtInstrumentConvertibleConversionPremiumShares	2500000	shares
CY2016Q1	pcrx	Debt Instrument Convertible Conversion Value DebtInstrumentConvertibleConversionValue	134500000	USD
CY2015Q4	pcrx	Foreign Property Plantand Equipment Net ForeignPropertyPlantandEquipmentNet	25900000	USD
CY2016Q1	pcrx	Foreign Property Plantand Equipment Net ForeignPropertyPlantandEquipmentNet	28400000	USD
CY2016Q1	pcrx	Goodwill Recordedfor Earn Out Payments GoodwillRecordedforEarnOutPayments	1904000	USD
CY2015Q1	pcrx	Income Lossfrom Continuing Operationsbefore Income Taxes Total IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal	1312000	USD
CY2016Q1	pcrx	Income Lossfrom Continuing Operationsbefore Income Taxes Total IncomeLossfromContinuingOperationsbeforeIncomeTaxesTotal	-3822000	USD
CY2015Q1	pcrx	Income Tax Provision IncomeTaxProvision	100000	USD
CY2016Q1	pcrx	Income Tax Provision IncomeTaxProvision	100000	USD
CY2015Q1	pcrx	Increase Decrease In Royalty Interest Obligation IncreaseDecreaseInRoyaltyInterestObligation	276000	USD
CY2016Q1	pcrx	Increase Decrease In Royalty Interest Obligation IncreaseDecreaseInRoyaltyInterestObligation	0	USD
CY2015	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	customer
CY2016Q1	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	customer
CY2012Q2	pcrx	Payment Obligation Arising Due To First Commercial Sale Of Product In Connection With Acquisition PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition	10000000	USD
CY2015Q1	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	1620000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8739000	USD
CY2016Q1	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	1904000	USD
CY2016Q1	pcrx	Total Goodwill Recordedfor Earn Out Payments TotalGoodwillRecordedforEarnOutPayments	16800000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10484000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25855000	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25901000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	35375000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	29067000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24917000	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	27997000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-52000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	49000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	526696000	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	538227000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8490000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7517000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8490000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2016Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2015Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1035000	USD
CY2016Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1022000	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1323000	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7304000	shares
CY2015Q4	us-gaap	Assets Assets	387735000	USD
CY2016Q1	us-gaap	Assets Assets	391206000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	252582000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	248625000	USD
CY2015Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	115495000	USD
CY2016Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	128413000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	33000	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	92000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	85000	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	43000	USD
CY2015Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1363000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1554000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37520000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40897000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56984000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35029000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36848319	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37103427	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36848319	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37103427	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	37000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	37000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1312000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3753000	USD
CY2015Q4	us-gaap	Convertible Debt ConvertibleDebt	118533000	USD
CY2016Q1	us-gaap	Convertible Debt ConvertibleDebt	118533000	USD
CY2015Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	104040000	USD
CY2016Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	105215000	USD
CY2015Q1	us-gaap	Cost Of Revenue CostOfRevenue	17580000	USD
CY2016Q1	us-gaap	Cost Of Revenue CostOfRevenue	20278000	USD
CY2016Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	2500000	shares
CY2016Q1	us-gaap	Debt Instrument Convertible Threshold Consecutive Trading Days DebtInstrumentConvertibleThresholdConsecutiveTradingDays	P30D
CY2016Q1	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	1.3
CY2016Q1	us-gaap	Debt Instrument Convertible Threshold Trading Days DebtInstrumentConvertibleThresholdTradingDays	20	D
CY2015Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	12605000	USD
CY2016Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	11583000	USD
CY2015Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1888000	USD
CY2016Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1735000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1426000	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1275000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8082000	USD
CY2016Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	7877000	USD
CY2015Q1	us-gaap	Depreciation Depreciation	2700000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	3100000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2743000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3165000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.03
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14919000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15000000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15000000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15000000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	81000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	USD
CY2015Q4	us-gaap	Goodwill Goodwill	30880000	USD
CY2016Q1	us-gaap	Goodwill Goodwill	32784000	USD
CY2012Q2	us-gaap	Goodwill Goodwill	8000000	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1886000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-3499000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1312000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3822000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-574000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-323000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	USD
CY2015Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	160000	USD
CY2016Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	142000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5679000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6227000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2145000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	46000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-356000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-356000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7001000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2099000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	29000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-419000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-372000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2917000	USD
CY2015Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1509000	USD
CY2016Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	6000	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	3652000	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	1000	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	0	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1885000	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2015Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	200000	USD
CY2016Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	300000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	1996000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	1868000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	2297000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	1926000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	32781000	USD
CY2016Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	37790000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	61645000	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	63744000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	16712000	USD
CY2016Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	16015000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	12152000	USD
CY2016Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9939000	USD
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	155000	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	252000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	169343000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	165036000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	387735000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	391206000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	149788000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	146139000	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	104040000	USD
CY2016Q1	us-gaap	Long Term Debt LongTermDebt	105215000	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	13462000	USD
CY2016Q1	us-gaap	Long Term Investments LongTermInvestments	13470000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	3377000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-21955000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4047000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3041000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	200000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-21875000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-870000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3121000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	1260000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-3854000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2029000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1568000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	54975000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	67728000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3341000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2254000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	45162000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	6420000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	8303000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	8081000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	7878000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	8731000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	5749000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	406000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	481000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	52000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	101000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	52000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	101000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11473000	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11020000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-117000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	48000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7874000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7053000	USD
CY2015Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	49937000	USD
CY2016Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	67843000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6117000	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8959000	USD
CY2015Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	59631000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	54925000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4047000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3041000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	115241000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	123843000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	90324000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	95846000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5967000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9493000	USD
CY2015Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	0	USD
CY2016Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	1085000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-308289000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-312143000	USD
CY2015Q1	us-gaap	Revenues Revenues	58316000	USD
CY2016Q1	us-gaap	Revenues Revenues	65474000	USD
CY2015Q1	us-gaap	Royalty Expense RoyaltyExpense	71000	USD
CY2016Q1	us-gaap	Royalty Expense RoyaltyExpense	0	USD
CY2015Q1	us-gaap	Royalty Revenue RoyaltyRevenue	874000	USD
CY2016Q1	us-gaap	Royalty Revenue RoyaltyRevenue	616000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	57086000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	64502000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31428000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37957000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7517000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8490000	USD
CY2016Q1	us-gaap	Share Price SharePrice	52.98
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	101981000	USD
CY2016Q1	us-gaap	Short Term Investments ShortTermInvestments	114992000	USD
CY2016Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
CY2016Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2016Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3041000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	218392000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	226170000	USD
CY2015Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	208000	USD
CY2016Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	98000	USD
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2016Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41779000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37020000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36235000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37020000	shares

Files In Submission

Name	View Source	Status
0001628280-16-015255-index-headers.html	Edgar Link	pending
0001628280-16-015255-index.html	Edgar Link	pending
0001628280-16-015255.txt	Edgar Link	pending
0001628280-16-015255-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pcrx-20160331.xml	Edgar Link	completed
pcrx-20160331.xsd	Edgar Link	pending
pcrx-20160331_cal.xml	Edgar Link	unprocessable
pcrx-20160331_def.xml	Edgar Link	unprocessable
pcrx-20160331_lab.xml	Edgar Link	unprocessable
pcrx-20160331_pre.xml	Edgar Link	unprocessable
pcrx-33116xex101.htm	Edgar Link	pending
pcrx-33116xex102.htm	Edgar Link	pending
pcrx-33116xex311.htm	Edgar Link	pending
pcrx-33116xex312.htm	Edgar Link	pending
pcrx-33116xex321.htm	Edgar Link	pending
pcrx-33116xex322.htm	Edgar Link	pending
pcrx-3312016x10xq.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCRX
Pacira BioSciences, Inc. Stock $pcrx

2016 Q1 Form 10-Q Financial Statement

#000162828016015255 Filed on May 02, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX Pacira BioSciences, Inc. Stock $pcrx

2016 Q1 Form 10-Q Financial Statement

#000162828016015255 Filed on May 02, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX
Pacira BioSciences, Inc. Stock $pcrx